Phillip G. Febbo
Known title: Chief Scientific & Med OfficerCIK: 0001649245
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Transaction History
| VCYT | ▼ Sell | Open Market | 10,405 | $446K | 9/4/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 2,705 | $118K | 9/4/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,639 | $163K | 9/2/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,730 | $178K | 6/2/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 29,603 | $0 | 3/6/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 6,578 | $0 | 3/6/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 6,035 | $217K | 3/2/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 13,425 | $485K | 3/2/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 71,806 | $0 | 2/26/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 24,486 | $949K | 2/26/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 2,955 | $136K | 12/2/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 8,349 | $301K | 10/6/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 2,955 | $89K | 9/2/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 2,955 | $79K | 6/2/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 24,160 | $0 | 3/6/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 4,467 | $147K | 3/4/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 3,570 | $121K | 3/4/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 6,754 | $235K | 3/2/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 15,672 | $530K | 2/27/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 30,589 | $0 | 2/27/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 3,934 | $173K | 12/4/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 6,738 | $297K | 12/2/2024 | View on chart |
| VCYT | ▲ Buy | Grant | 39,904 | $0 | 3/6/2024 | View on chart |
| VCYT | ▲ Buy | Grant | 53,182 | $0 | 10/2/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 7,556 | $0 | 3/1/2023 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 3,522 | $0 | 2/21/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,245 | $253K | 2/21/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 821 | $178K | 11/5/2022 | View on chart |
| ILMN | ▼ Sell | Open Market | 1,988 | $716K | 4/6/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 131 | $48K | 4/5/2022 | View on chart |
| ILMN | ▲ Buy | Grant | 3,029 | $0 | 3/1/2022 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 2,851 | $0 | 2/22/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,002 | $320K | 2/22/2022 | View on chart |
| ILMN | ▼ Sell | Open Market | 1,000 | $407K | 11/8/2021 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 446 | $182K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.